EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI

Anssi Auvinen, Teuvo L J Tammela, Tuomas Mirtti, Hans Lilja, Teemu Tolonen, Anu Kenttämies, Irina Rinta-Kiikka, Terho Lehtimäki, Kari Natunen, Jaakko Nevalainen, Jani Raitanen, Johanna Ronkainen und 8 weitere

JAMA · 07.05.2024 · 331 (17) · 1452

DOI: 10.1001/jama.2024.3841 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA, erschienen am 07.05.2024. Verfasst von Anssi Auvinen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Tampere University, Unit of Health Sciences, Faculty of Social Sciences, Tampere, Finland. Hauptthemen laut MEDLINE: Early Detection of Cancer, Prostatic Neoplasms. Die Arbeit wurde bisher 122-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Prostate-specific antigen (PSA) screening has potential to reduce prostate cancer mortality but frequently detects prostate cancer that is not clinically important.

Objective

To describe rates of low-grade (grade group 1) and high-grade (grade groups 2-5) prostate cancer identified among men invited to participate in a prostate cancer screening protocol consisting of a PSA test, a 4-kallikrein panel, and a magnetic resonance imaging (MRI) scan. Design, Setting, and Participants The ProScreen trial is a clinical trial conducted in Helsinki and Tampere, Finland, that randomized 61 193 men aged 50 through 63 years who were free of prostate cancer in a 1:3 ratio to either be invited or not be invited to undergo screening for prostate cancer between February 2018 and July 2020.

Interventions

Participating men randomized to the intervention underwent PSA testing. Those with a PSA level of 3.0 ng/mL or higher underwent additional testing for high-grade prostate cancer with a 4-kallikrein panel risk score. Those with a kallikrein panel score of 7.5% or higher underwent an MRI of the prostate gland, followed by targeted biopsies for those with abnormal prostate gland MRI findings. Final data collection occurred through June 31, 2023. Main Outcomes and Measures In descriptive exploratory analyses, the cumulative incidence of low-grade and high-grade prostate cancer after the first screening round were compared between the group invited to undergo prostate cancer screening and the control group.

Results

Of 60 745 eligible men (mean [SD] age, 57.2 [4.0] years), 15 201 were randomized to be invited and 45 544 were randomized not to be invited to undergo prostate cancer screening. Of 15 201 eligible males invited to undergo screening, 7744 (51%) participated. Among them, 32 low-grade prostate cancers (cumulative incidence, 0.41%) and 128 high-grade prostate cancers (cumulative incidence, 1.65%) were detected, with 1 cancer grade group result missing. Among the 7457 invited men (49%) who refused participation, 7 low-grade prostate cancers (cumulative incidence, 0.1%) and 44 high-grade prostate cancers (cumulative incidence, 0.6%) were detected, with 7 cancer grade groups missing. For the entire invited screening group, 39 low-grade prostate cancers (cumulative incidence, 0.26%) and 172 high-grade prostate cancers (cumulative incidence, 1.13%) were detected. During a median follow-up of 3.2 years, in the group not invited to undergo screening, 65 low-grade prostate cancers (cumulative incidence, 0.14%) and 282 high-grade prostate cancers (cumulative incidence, 0.62%) were detected. The risk difference for the entire group randomized to the screening invitation vs the control group was 0.11% (95% CI, 0.03%-0.20%) for low-grade and 0.51% (95% CI, 0.33%-0.70%) for high-grade cancer. Conclusions and Relevance In this preliminary descriptive report from an ongoing randomized clinical trial, 1 additional high-grade cancer per 196 men and 1 low-grade cancer per 909 men were detected among those randomized to be invited to undergo a single prostate cancer screening intervention compared with those not invited to undergo screening. These preliminary findings from a single round of screening should be interpreted cautiously, pending results of the study’s primary mortality outcome. Trial Registration ClinicalTrials.gov Identifier: NCT03423303

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Early Detection of CancerProstatic NeoplasmsHumansMaleMiddle AgedBiopsyKallikreinsMagnetic Resonance ImagingNeoplasm GradingProstateProstate-Specific AntigenRiskFinlandScandinavians and Nordic PeopleBiomarkers, Tumor

Substanzen

KallikreinsProstate-Specific AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • Tampere University, Unit of Health Sciences, Faculty of Social Sciences, Tampere, Finland.
  • Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland.
  • Department of Urology, Tays Cancer Centre, Tampere University Hospital, Tampere, Finland.
  • Helsinki University Hospital, Department of Pathology, Helsinki, Finland.
  • University of Helsinki, Faculty of Medicine, Helsinki, Finland.
  • iCAN-Digital Precision Cancer Medicine Flagship, Helsinki, Finland.

Förderung

  • NCI NIH HHS

Zitieren

APA

Auvinen, A., Tammela, T. L. J., Mirtti, T., Lilja, H., Tolonen, T., Kenttämies, A., Rinta-Kiikka, I., Lehtimäki, T., Natunen, K., Nevalainen, J., Raitanen, J., Ronkainen, J., van der Kwast, T., Riikonen, J., Pétas, A., Matikainen, M., Taari, K., Kilpeläinen, T., Rannikko, A. S., & ProScreen Trial Investigators (2024). Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI. JAMA, 331(17), 1452. https://doi.org/10.1001/jama.2024.3841

Vancouver

Auvinen A, Tammela TLJ, Mirtti T, Lilja H, Tolonen T, Kenttämies A, et al. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI. JAMA. 2024;331(17):1452. doi:10.1001/jama.2024.3841

BibTeX
@article{Auvinen2024,
  author = {Auvinen, Anssi and Tammela, Teuvo L J and Mirtti, Tuomas and Lilja, Hans and Tolonen, Teemu and Kenttämies, Anu and Rinta-Kiikka, Irina and Lehtimäki, Terho and Natunen, Kari and Nevalainen, Jaakko and Raitanen, Jani and Ronkainen, Johanna and van der Kwast, Theodorus and Riikonen, Jarno and Pétas, Anssi and Matikainen, Mika and Taari, Kimmo and Kilpeläinen, Tuomas and Rannikko, Antti S and ProScreen Trial Investigators, ProScreen Trial Investigators},
  title = {Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI},
  journal = {JAMA},
  year = {2024},
  volume = {331},
  number = {17},
  pages = {1452},
  doi = {10.1001/jama.2024.3841}
}
Kostenlos starten →